Grifols (GRFS) Cash from Operations (2010 - 2020)
Grifols' (GRFS) quarterly Cash from Operations came in at 116320951.13 in Q1 2020, up 161.02% YoY from 44564177.7 in Q2 2019, and down 69.02% on a QoQ basis from 375465153.7 in Q4 2019.
Grifols (GRFS) Cash from Operations (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Cash from Operations data on file, last reported at 116320951.13 in Q1 2020.
- Quarterly Cash from Operations rose 161.02% year-over-year to 116320951.13 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was 767696482.23 (up 33.15% YoY) and the FY2025 annual result came in at 1218753559.89, up 26.44% from the prior year.
- Cash from Operations declined to 116320951.13 in Q1 2020, from 375465153.7 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 671810029.36 in Q4 2017 to a low of 190630846.21 in Q1 2019.
- A 5-year average of 234197285.45 and a median of 194784409.05 in 2016 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2017 — Cash from Operations soared 244.9% — and 2019, when it plunged 267.38%.
- Tracing GRFS's Cash from Operations over 5 years: stood at 194784409.05 in 2016, then soared by 244.9% to 671810029.36 in 2017, then plunged by 30.55% to 466541223.61 in 2018, then decreased by 19.52% to 375465153.7 in 2019, then tumbled by 69.02% to 116320951.13 in 2020.
- The last three Cash from Operations figures came in at 116320951.13 (Q1 2020), 375465153.7 (Q4 2019), and 190630846.21 (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 116.32 Mn |
| Mar 31, 2020 | 116.32 Mn |
| Dec 31, 2019 | 375.47 Mn |
| Dec 31, 2019 | 375.47 Mn |
| Mar 31, 2019 | -190.63 Mn |
| Mar 31, 2019 | -190.63 Mn |
| Dec 31, 2018 | 466.54 Mn |
| Dec 31, 2018 | 466.54 Mn |
| Jun 30, 2018 | 186.75 Mn |
| Jun 30, 2018 | 186.75 Mn |
| Mar 31, 2018 | 113.89 Mn |
| Mar 31, 2018 | 113.89 Mn |
| Dec 31, 2017 | 671.81 Mn |
| Dec 31, 2017 | 671.81 Mn |
| Jun 30, 2017 | 256.39 Mn |
| Jun 30, 2017 | 256.39 Mn |
| Mar 31, 2017 | 154.89 Mn |
| Mar 31, 2017 | 154.89 Mn |
| Dec 31, 2016 | 194.78 Mn |
| Dec 31, 2016 | 194.78 Mn |